Cardiovascular risk factors in coeliac disease (ARCTIC): a protocol of multicentre series of studies

• Published in: BMJ Open
• Main Authors: Vereczkei, Zsófia, Imrei, Marcell, Szakács, Zsolt, Kővári, Bálint, Papp, Veronika, Lénárt, Zsuzsanna, Berki, Tímea, Szirmay, Balázs, Farkas, Nelli, Balaskó, Márta, Habon, Tamás, Hegyi, Péter, Bajor, Judit
• Other Authors: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Pécsi Tudományegyetem
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMJ 2023
• Subjects: General Medicine; Arctic
• Online Access: http://dx.doi.org/10.1136/bmjopen-2022-068989; https://syndication.highwire.org/content/doi/10.1136/bmjopen-2022-068989

Introduction There is only limited and controversial information available on the cardiovascular (CV) risk in coeliac disease (CD). In this study, we plan to investigate the body composition and CV risk-related metabolic parameters at the diagnosis of CD and on a gluten-free diet in a Hungarian cohort of patients with CD. Methods and analysis This study consists of two case–control studies and a prospective cohort study, involving newly diagnosed and treated patients with CD with age and sex-matched non-CD control subjects with an allocation ratio of 1:1. CD-related symptoms, quality of life, quality of the diet and CV risk will be assessed with questionnaires. Our primary outcomes are body composition parameters, which will be estimated with InBody 770 device. Secondary outcomes are CV-risk related metabolic parameters (eg, serum lipids, haemoglobin A1c, homeostatic model assessment index, liver enzymes, homocysteine, interleukin 6, galectin-3) and enteral hormones (leptin, ghrelin, adiponectin) measured from venous blood samples for all participants. Fatty liver disease will be assessed by transabdominal ultrasonography. In statistical analysis, descriptive and comparative statistics will be performed. With this study, we aim to draw attention to the often neglected metabolic and CV aspect of the management of CD. Findings may help to identify parameters to be optimised and reassessed during follow-up in patients with CD. Ethics and dissemination The study was approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (27521-5/2022/EÜIG). Findings will be disseminated at research conferences and in peer-reviewed journals. Trial registration number NCT05530070 .